180 related articles for article (PubMed ID: 6543419)
1. [Fungal infections: involved species and minimal inhibitory concentrations of common antifungal agents].
Dei-Cas E; Fruit J; Poulain D; Dutoit E; Chendid H; Vernes A
Ann Biol Clin (Paris); 1984; 42(6):415-8. PubMed ID: 6543419
[TBL] [Abstract][Full Text] [Related]
2. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance.
Krcmery V; Barnes AJ
J Hosp Infect; 2002 Apr; 50(4):243-60. PubMed ID: 12014897
[TBL] [Abstract][Full Text] [Related]
3. Candida krusei fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital.
Muñoz P; Sánchez-Somolinos M; Alcalá L; Rodríguez-Créixems M; Peláez T; Bouza E
J Antimicrob Chemother; 2005 Feb; 55(2):188-93. PubMed ID: 15650001
[TBL] [Abstract][Full Text] [Related]
4. Survey of amphotericin B susceptibility of Candida clinical isolates determined by Etest.
Chiu YS; Chang SC; Hsueh PR; Wang JL; Sun HY; Chen YC
J Microbiol Immunol Infect; 2006 Aug; 39(4):335-41. PubMed ID: 16926981
[TBL] [Abstract][Full Text] [Related]
5. In vitro antifungal susceptibility of clinical isolates of Candida spp. obtained from patients with different predisposing factors to candidosis.
Pinto PM; Weikert-Oliveira Rde C; Lyon JP; Cury VF; Arantes RR; Koga-Ito CY; Resende MA
Microbiol Res; 2008; 163(5):579-85. PubMed ID: 16962755
[TBL] [Abstract][Full Text] [Related]
6. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S
J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology of candidemia in a Turkish tertiary care hospital.
Bakir M; Cerikcioglu N; Barton R; Yagci A
APMIS; 2006 Sep; 114(9):601-10. PubMed ID: 16948812
[TBL] [Abstract][Full Text] [Related]
8. Candida albicans versus non-albicans bloodstream infection in patients in a tertiary hospital: an analysis of microbiological data.
Samonis G; Kofteridis DP; Saloustros E; Giannopoulou KP; Ntziora F; Christidou A; Maraki S; Falagas ME
Scand J Infect Dis; 2008; 40(5):414-9. PubMed ID: 18418802
[TBL] [Abstract][Full Text] [Related]
9. Candidemia and the susceptibility pattern of Candida isolates in blood.
Osoba AO; Al-Mowallad AW; McAlear DE; Hussein BA
Saudi Med J; 2003 Oct; 24(10):1060-3. PubMed ID: 14578968
[TBL] [Abstract][Full Text] [Related]
10. EUCAST technical note on Amphotericin B.
Lass-Flörl C; Arendrup MC; Rodriguez-Tudela JL; Cuenca-Estrella M; Donnelly P; Hope W;
Clin Microbiol Infect; 2011 Dec; 17(12):E27-9. PubMed ID: 22011310
[TBL] [Abstract][Full Text] [Related]
11. Susceptibilities to amphotericin B and fluconazole of Candida species in Taiwan Surveillance of Antimicrobial Resistance of Yeasts 2006.
Yang YL; Wang AH; Wang CW; Cheng WT; Li SY; Lo HJ;
Diagn Microbiol Infect Dis; 2008 Jun; 61(2):175-80. PubMed ID: 18304773
[TBL] [Abstract][Full Text] [Related]
12. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy.
Antoniadou A; Torres HA; Lewis RE; Thornby J; Bodey GP; Tarrand JP; Han XY; Rolston KV; Safdar A; Raad II; Kontoyiannis DP
Medicine (Baltimore); 2003 Sep; 82(5):309-21. PubMed ID: 14530780
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the etest method using Mueller-Hinton agar with glucose and methylene blue for determining amphotericin B MICs for 4,936 clinical isolates of Candida species.
Pfaller MA; Boyken L; Messer SA; Tendolkar S; Hollis RJ; Diekema DJ
J Clin Microbiol; 2004 Nov; 42(11):4977-9. PubMed ID: 15528683
[TBL] [Abstract][Full Text] [Related]
14. In vitro susceptibility of Candida species isolated from blood culture to some antifungal agents.
Citak S; Ozçelik B; Cesur S; Abbasoğlu U
Jpn J Infect Dis; 2005 Feb; 58(1):44-6. PubMed ID: 15728993
[TBL] [Abstract][Full Text] [Related]
15. Antifungal susceptibility of epigallocatechin 3-O-gallate (EGCg) on clinical isolates of pathogenic yeasts.
Park BJ; Park JC; Taguchi H; Fukushima K; Hyon SH; Takatori K
Biochem Biophys Res Commun; 2006 Aug; 347(2):401-5. PubMed ID: 16831406
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of 6 antifungal agents on candida species isolated as causative agents from vaginal and other clinical specimens.
Ellabib MS; ElJariny IA
Saudi Med J; 2001 Oct; 22(10):860-3. PubMed ID: 11744942
[TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibility of 115 isolates of Candida to amphotericin B, fluconazole and itraconazole.
Mallié M; Bastide JM
Drugs Exp Clin Res; 1996; 22(6):301-7. PubMed ID: 9034756
[TBL] [Abstract][Full Text] [Related]
18. Amphotericin B-induced in vitro postantifungal effect on Candida species of oral origin.
Ellepola AN
Med Princ Pract; 2012; 21(5):442-6. PubMed ID: 22678101
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of Candida species in different hospital wards and their susceptibility to antifungal agents: results of a three year survey.
Fadda ME; Podda GS; Pisano MB; Deplano M; Cosentino S
J Prev Med Hyg; 2008 Jun; 49(2):69-74. PubMed ID: 18847180
[TBL] [Abstract][Full Text] [Related]
20. Susceptibilities to amphotericin B and fluconazole of Candida species in TSARY 2002.
Yang YL; Li SY; Cheng HH; Lo HJ;
Diagn Microbiol Infect Dis; 2005 Mar; 51(3):179-83. PubMed ID: 15766603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
